Critical Therapeutics
As of the edition of 20 October 2026, Critical Therapeutics runs 4 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Zileuton | none listed | 1 |
| Reteplase | Ended 2008 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where its trials are
- Heart and blood vessels: 1 trials led
- Infections: 1 trials led